BOTHELL, Wash., Nov. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. will be hosting a Webinar to discuss the science of RNA interference (RNAi), its emerging siRNA therapeutics programs and siRNA drug delivery technology. Details follow:
What: Webinar on the science of RNAi and the Company’s RNAi therapeutics programs followed by a Q&A session. Questions may be emailed in advance to rnaiwebinar@nastech.com or during the event through the webinar interface. When: Thursday, November 9, 2006, from 10:30-11:15 a.m. Eastern Time. How: Live over the Internet at http://www.nastech.com. Please connect to the webinar via Nastech’s website several minutes prior to the start of the live conference call to ensure adequate time for any software download that may be necessary. You may also listen to the live event and ask questions by phone. U.S. callers should dial 800-259-0251 and international callers should dial 617-614-3671. The passcode is 41863763. To listen to a replay of the event by telephone, U.S. callers should dial 888-286-8010 and international callers should dial 617-801-6888. The passcode for the telephonic replay is 31087376. If you are unable to participate during the live RNAi webinar webcast, an archive and replay will be available for 30 days via Nastech’s website at http://www.nastech.com. About Nastech
Nastech is a pharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, diabetes, obesity, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech’s and/or a partner’s ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech’s and/or a partner’s ability to obtain required governmental approvals; and (v) Nastech’s and/or a partner’s ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech’s most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
CONTACTS: Nastech Ed Bell Senior Investor Relations Manager (425) 908-3639 ir@nastech.com Noonan Russo Matthew Haines (Investors/Media) (212) 845-4235
Nastech Pharmaceutical Company Inc.
CONTACT: Ed Bell, Senior Investor Relations Manager of NastechPharmaceutical Company Inc., +1-425-908-3639, ir@nastech.com; or Investors& Media: Matthew Haines of Noonan Russo, +1-212-845-4235, for NastechPharmaceutical Company Inc.
Web site: http://www.nastech.com/
